RNA-guided diagnostics and therapeutics for next-generation individualized nanomedicine

Journal of Clinical Investigation

Volumn 123, Issue 6, 2013, Pages 2350-2352

  Glinsky, Gennadi V ^a,b,c  

^a BURNHAM INSTITUTE   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Translational and Functional Genomics Laboratory   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; MICRORNA 205; MICRORNA 375; RNA; SMALL INTERFERING RNA; SMALL UNTRANSLATED RNA; UNTRANSLATED RNA;

CANCER MORTALITY; CANCER SPECIFIC SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CELL DIFFERENTIATION; CHROMATIN; CLINICAL LABORATORY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION; HEALTH CARE QUALITY; HUMAN; MOLECULAR DIAGNOSIS; NANOMEDICINE; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SURVIVAL RATE; UNITED STATES;

ANIMALS; CARCINOMA, BASAL CELL; CARCINOMA, MERKEL CELL; HUMANS; MICRORNAS; SKIN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84878558207     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI69268     Document Type: Review

References (28)

1. DeFrances CJ, Lucas CA, Buie VC, Golosinskiy A. 2006 National Hospital Discharge Survey. Natl Health Stat Report. 2008;(5):1-20.
2. Draisma G, et al. Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst. 2003;95(12):868-878.
3. Schröder FH, et al. Screening and prostate-cancer mortality in a randomized european study. N Engl J Med. 2009;360(13):1320-1328.
4. Hugosson J, et al. Mortality results from the Göteborg randomised population-based prostate-cancer screening trial. Lancet Oncol. 2010;11(8):725-732.
5. Stattin P, et al. Outcomes in localized prostate cancer: National Prostate Cancer Register of Sweden follow-up study. J Natl Cancer Inst. 2010; 102(13):950-958.
6. Tosoian JJ, et al. Active surveillance program for prostate cancer: an update of the Johns Hopkins experience. J Clin Oncol. 2011;29(16):2185-2190.
7. Rinn JL, Chang HY. Genome regulation by long noncoding RNAs. Annu Rev Biochem. 2012;81:145-166.
8. Glinsky GV. Phenotype-defining functions of multiple non-coding RNA pathways. Cell Cycle. 2008;7(11):1630-1639.
9. Lee JT. Epigenetic regulation by long noncoding RNAs. Science. 2012;338(6113):1435-1439.
10. Wang KC, Chang HY. Molecular mechanisms of long noncoding RNAs. Mol Cell. 2011;43(6):904-914.
11. Glinskii AB, et al. Identification of intergenic trans-regulatory RNAs containing a disease-linked SNP sequence and targeting cell cycle progression/differentiation pathways in multiple common human disorders. Cell Cycle. 2009;8(23):3925-3942.
12. Martin L, Chang HY. Uncovering the role of genomic "dark matter" in human disease. J Clin Invest. 2012;122(5):1589-1595.
13. Glinskii AB, et al. Networks of intergenic longrange enhancers and snpRNAs drive castrationresistant phenotype of prostate cancer and contribute to pathogenesis of multiple common human disorders. Cell Cycle. 2011;10(20):3571-3597.
14. Lightfoot HL, Hall J. Target mRNA inhibition by oligonucleotide drugs in man. Nucleic Acids Res. 2012;40(21):10585-10595.
15. Olsen AL, Davies JM, Medley L, Breen D, Talbot DC, McHugh PJ. Quantitative analysis of survivin protein expression and its therapeutic depletion by an antisense oligonucleotide in human lung tumors. Mol Ther Nucleic Acids. 2012;1:e30.
16. Callies S, et al. Integrated analysis of preclinical data to support the design of the first in man study of LY2181308, a second generation antisense oligonucleotide. Br J Clin Pharmacol. 2011;71(3):416-428.
17. Lindow M, Kauppinen S. Discovering the first microRNA-targeted drug. J Cell Biol. 2012; 199(3):407-412.
18. Chisholm KM, Wan Y, Li R, Montgomery KD, Chang HY, West RB. Detection of long non-coding RNA in archival tissue: correlation with polycomb protein expression in primary and metastatic breast carcinoma. PLoS One. 2012;7(10):e47998.
19. Brunner AL, et al. Transcriptional profiling of lncRNAs and novel transcribed regions across a diverse panel of archived human cancers. Genome Biol. 2012;13(8):R75.
20. Renwick N, et al. Multicolor microRNA FISH effectively differentiates tumor types. J Clin Invest. 2013;123(6):2694-2702.
21. Zardo G, et al. Polycombs and microRNA-223 regulate human granulopoiesis by transcriptional control of target gene expression. Blood. 2012;119(17):4034-4046.
22. Zardo G, et al. Transcriptional targeting by microRNA-polycomb complexes: a novel route in cell fate determination. Cell Cycle. 2012;11(19):3543-3549.
23. Braun GB, et al. Laser-activated gene silencing via Gold NanoshellsiRNA conjugates. ACS Nano. 2009;3(7):2007-2015.
24. Lu W, et al. Tumor site-specific silencing of NF-kappaB p65 by targeted hollow gold nanosphere-mediated photothermal transfection. Cancer Res. 2010;70(8):3177-3188.
25. Lee SE, et al. Photonic gene circuits by optically addressable siRNA-Au nanoantennas. ACS Nano. 2012;6(9):7770-7780.
26. Ren Y, et al. Targeted tumor-penetrating siRNA nanocomplexes for credentialing the ovarian cancer oncogene ID4. Sci Transl Med. 2012;4(147):147ra112.
27. Landon PB, Ramachandran S, Gillman A, Gidron T, Yoon D, Lal R. DNA zipper-based tweezers. Langmuir. 2012;28(1):534-540.
28. Glinsky GV, Berezovska O, Glinskii AB. Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer. J Clin Invest. 2005;115(6):1503-1521.